Supplementary Table I: Postmarketing Safety of Bimekizumab for Hidradenitis Suppurativa: An Early Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://data.mendeley.com/datasets/wxnmgt7khb
下载链接
链接失效反馈官方服务：
资源简介：
Clinical Characteristics of Adverse Event (AE) Reports Associated with Bimekizumab in the treatment of Hidradenitis Suppurativa (n=239 AE reports total). AE, Adverse Event.
创建时间：
2026-01-26
